Technology transfer / Localization · GCC · Announced 28 Oct 2025

Local Content and Government Procurement Authority → Sudair Pharma

Saudi Arabia's LCGPA signed an agreement with Sudair to localise nilotinib capsules, a cancer treatment, at the Global Health Exhibition 2025 in Riyadh.

Parties: Local Content and Government Procurement Authority (LCGPA) (Saudi Arabia) → Sudair Pharma (Saudi Arabia)

Value
Undisclosed
Territory
Saudi Arabia — local manufacturing and knowledge transfer
Therapeutic area
Oncology
Asset
nilotinib
Announced
28 Oct 2025

Our analysis

Why this matters

On 28 October 2025, at the Global Health Exhibition in Riyadh, Saudi Arabia's Local Content and Government Procurement Authority (LCGPA) signed five localisation agreements. One covered nilotinib capsules, a cancer treatment, and was signed separately with three companies: Tabuk Pharmaceuticals, a company named only as "Pharma", and Sudair (named in the source as شركة سدير).

No value was given for each agreement. The LCGPA expects the five agreements together to add more than SAR 1.2 billion to GDP and about 500 direct jobs. Single source: Al Watan. Our reading is that "Sudair" refers to Sudair Pharma; the source gives only the short name.

The full analysis is free to read with a work email on this page.

Source: Al Watan (Saudi Arabia)

More deals involving Local Content and Government Procurement Authority or Sudair Pharma

Latest deals

All GCC deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →